Objective: Autosomal-recessive mutations in TBCK cause intellectual disability of variable severity. Although the physiological function of TBCK remains unclear, loss-of-function mutations are associated with inhibition of mechanistic target of rapamycin complex 1 (mTORC1) signaling. Given that mTORC1 signaling is known to regulate autophagy, we hypothesized that TBCK-encephalopathy patients with a neurodegenerative course have defects in autophagic-lysosomal dysfunction. Methods: Children (n 5 8) of Puerto Rican (Boricua) descent affected with homozygous TBCK p.R126X mutations underwent extensive neurological phenotyping and neurophysiological studies. We quantified autophagosome content in TBCK 2/2 patient-derived fibroblasts by immunostaining and assayed autophagic markers by western assay. Free sialylated oligosaccharide profiles were assayed in patient's urine and fibroblasts. Results: The neurological phenotype of children with TBCK p.R126X mutations, which we call TBCKencephaloneuronopathy (TBCKE), include congenital hypotonia, progressive motor neuronopathy, leukoencephalopathy, and epilepsy. Systemic features include coarse facies, dyslipidemia, and osteoporosis. TBCK 2/2 fibroblasts in vitro exhibit increased numbers of LC3 1 autophagosomes and increased autophagic flux by immunoblots. Free oligosaccharide profiles in fibroblasts and urine of TBCKE patients differ from control fibroblasts and are ameliorated by treatment with the mTORC1 activator leucine. Interpretation: TBCKE is a clinically distinguishable syndrome with progressive central and peripheral nervous system dysfunction, consistently observed in patients with the p.R126X mutation. We provide evidence that inappropriate autophagy in the absence of cellular stressors may play a role in this disorder, and that mTORC1 activation may ameliorate the autophagic-lysosomal system dysfunction. Free oligosaccharide profiles could serve as a novel biomarker for this disorder as well as a tool to evaluate potential therapeutic interventions.
phenotypic spectrum reported with TBCK mutations is quite variable. [1] [2] [3] [4] [5] [6] Whereas some children have nonprogressive, mild ID, autistic features, and limited motor impairment, 2 others have profound ID, progressive leukoencephalopathy, and brain atrophy along with extreme neuromuscular weakness, medication refractory epilepsy, and chronic respiratory failure. Although little is known about the function of TBCK, previous studies link loss of function of TBCK to changes in mTOR (mechanistic target of rapamycin) signaling output. 7 The mTOR pathway regulates crucial cellular responses, including growth, apoptosis, autophagy, and energy metabolism. 8 mTOR pathway signaling activity is regulated by growth factors, insulin, and amino acids. 9 mTOR is a ser/thr kinase that interacts with select protein binding partners to form two distinct complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Augmented mTOR signaling is central to the pathogenesis of tuberous sclerosis complex and other neurodevelopmental disorders, such as cortical dysplasia and megalencephaly, that share symptoms of autism and epilepsy. 10, 11 To date, most neurological disorders associated with aberrant mTORC1 signaling result from overactivation of the mTOR pathway. 10 On the other hand, TBCKE is distinctly characterized by inhibition of mTORC1 signaling. 1,2 A few neurodevelopmental disorders have been linked to mTOR inhibition, including Rett syndrome, 12, 13 Phelan-McDermid syndrome, 14 and
Galloway-Mowat 15 syndrome. Clinically, all of these disorders are also associated with ID and epilepsy. TBCK encodes its homonym protein, TBC1-domain containing Kinase, which contains a TBC (Tre-2, Bub2, and Cdc16) domain flanked by an N-terminal kinase-like domain and a rhodanese homology domain at the C-terminus. Sequence homology suggests that TBCK encodes a Rab GTPase-activating protein, although this remains unproven. 7 TBCK messenger RNA and protein appear to be expressed in most tissues of the human body, and mouse brain transcriptome data suggest expression in astrocytes, neurons, and oligodendrocytes. Knockdown of TBCK expression using RNA interference decreases phosphorylation of mTORC1 targets, such as 4eBP1 (Thr37/46) and p70S6K (Thr389), in HEK293 cells. 7 Consistently, a >70% decrease in pS6K phosphorylation was found in TBCK-encephalopathy patient's lymphocytes. mTORC1 signaling is known to regulate autophagy, the process by which proteins, lipids, and organelles are trafficked to lysosomes for degradation. 16, 17 Autophagy defects are emerging as a final common pathway in neurodegenerative disorders across the age spectrum, from lysosomal storage disorders to Parkinson's disease. 17 Given that loss of function of TBCK leads to mTORC1 signaling inhibition and mTORC1 inhibitors are known to induce autophagy, we hypothesized that cells from patients with progressive neurodegeneration associated with TBCKE would exhibit enhanced autophagy activity. Here, we report that patient-derived fibroblasts homozygous for TBCK p.R126X mutations have increased LC3b-positive autophagosomes and autophagic flux. In line with suspected autophagic-lysosomal dysfunction, we also found deficits in degradation of glycosylated proteins (as reflected on oligosaccharide profiles), thus constituting a novel disease biomarker for TBCK encephalopathy.
Subjects and Methods

Patients and Whole Exome Sequencing
All patients were diagnosed or referred to the pediatric neurogenetics program at the Children's Hospital of Philadelphia. Patient 126-1 underwent research whole exome sequencing (WES) at the University of Washington, whereas patient 126-2 was diagnosed based on clinical WES. Both were part of the cohort leading to our earlier report that TBCK mutations cause congenital hypotonia and severe infantile encephalopathy. 1 Before our report, the TBCK p.R126X mutation was also identified in a family with 2 affected siblings (patients 126-4 and 126-5) by research WES at the National Institutes of Health (NIH). All additional patients were diagnosed by clinical WES. The studies were approved by the corresponding institutional review board committees of the Children's Hospital of Philadelphia, University of Washington, and the NIH. Informed consent was obtained from all participants. All patients reported here are of Puerto Rican ancestry without a history of consanguinity, consistent with a founder mutation. We termed this the "Boricua" mutation, because this is the self-identification term often preferred by inhabitants of Puerto Rico and their descendants.
Characterization of Neurological Phenotype
All patients underwent diagnostic brain magnetic resonance imagings (MRIs) as part of neurological evaluations for severe encephalopathy and global developmental delays. Given clinical concerns for developmental regression, and in 1 patient metabolic stroke, some patients underwent muscle biopsies and evaluation for mitochondrial disorders. Because of progressive, severe neuromuscular weakness, which is not a consistent feature among TBCK-encephalopathy patients, we extensively characterized the neuromuscular phenotype by performing muscle ultrasound, nerve conduction studies (NCS), and electromyography (EMG) with standard techniques. Muscle ultrasound was performed during illness when possible because of a history of clinically evident fasciculations in some patients, which was more prominent with illness. Nerve and muscle biopsies were reviewed when available.
Skin Biopsy and Immunocytochemical Studies
Patients underwent skin biopsy (3-mm punch biopsy) as part of their diagnostic workup. Primary fibroblasts were maintained in Dulbecco's modified Eagle's medium with 15% fetal bovine serum (FBS), nonessential amino acids, and glutamax. Control primary fibroblasts (n 5 3 lines, comparable ages) were commercially obtained (Coriell Institute, Camden, NJ) and genotyped (by TBCK targeted Sanger sequencing) to confirm normal sequence. Immunocytochemical staining was performed on fibroblasts plated onto #1.5 coverslips under basal conditions. Following 4% paraformaldehyde fixation, cells were blocked with 2% normal goat serum and 0.01% triton for 1 hour at room temperature, and then incubated with rabbit anti-Anti-LC3b (LC3II; Abcam, Cambridge, UK) overnight at 48C. Secondary anti-Rabbit Alexa555 was incubated for 2 hours in room temperature. Cells were imaged using a Zeiss LSM710 confocal system (Carl Zeiss, Jena, Germany). Imaging analysis for quantification of LC3b puncta and colocalization analysis was performed in with the Zeiss Zen Blue analysis software. Statistical analysis was performed using GraphPad Prism (GraphPad Software Inc., La Jolla, CA), with a p value <0.05 considered significant.
Western Assay
Fibroblasts were grown in routine culture conditions, seeded at 150,000 cells per six-well plate, and harvested 24 hours postplating. For serum-free experiments, cells were plated at the same density as above, maintained 24 hours in similar media except for removal of FBS, and subsequently treated with chloroquine 50 lM (4 hours; Sigma-Aldrich, St. Louis, MO) or L-Leucine 600 lg/ml (5 hours; Sigma-Aldrich). Proteins were extracted with ultrapure water and 1 3 Laemmli buffer (#161-0747; BioRad; Hercules, CA) and sonicated 25 seconds at the power of 160 watts (in two rounds of ice). 18 Membranes (polyvinylidene difluoride) were probed with antibodies recognizing Beclin-1 Oligosaccharide Analysis by Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry TBCK 2/2 fibroblasts and controls were assayed to obtain oligosaccharide profiles by MALDI-TOF (matrix assisted laser desorption/ionization-time of flight) mass spectroscopy as previously described, with minor modification. Free oligosaccharides from cell lysate of 400 lg of total protein were separated from cellular proteins using a 10-kDa size exclusion column, purified through C18 and carbograph solid-phase extraction columns, and were permethylated before being subjected to MALDI-TOF analysis. Urine specimens were also analyzed. Fibroblasts were treated with rapamycin 100nM or 600 lg/ml of leucine for 16 hours before harvesting for oligosaccharide assays. All patients have profound intellectual disability, with at most having few words of expressive language that were subsequently lost. All patients were found to be areflexic on neurological exam within the first year of life. All patients in our cohort had head circumferences within the normal range at birth and during childhood. All children exhibited recognizable dysmorphic features, most remarkably showing progressive coarsening of facial features, bitemporal narrowing, and macroglossia.
Results
Upper and lower limbs were grossly brachymelic and hands and feet demonstrated acromelia (not measured, by clinical impression; Fig 1) .
TBCK p.R126X Causes Progressive Neuromuscular Weakness and Chronic Respiratory Failure All patients had a clinical history of hypotonia and were areflexic since infancy, leading to initial genetic evaluations for spinal muscular atrophy in some. Early motor milestones were significantly delayed in all, with only 1 of the children achieving the ability to sit unsupported. Beyond significant global delays since infancy, all children have exhibited some evidence of developmental regression by teenage years. Head control and voluntary reaching were achieved during the first years of life and subsequently lost. All of them have distal > proximal muscle atrophy and profound muscle weakness. Six of the 8 boys developed chronic respiratory failure, 5 are ventilator-dependent (with tracheostomy). The 2 patients without evidence of respiratory failure in our cohort are the youngest (3 and 5 years old), consistent with neuromuscular weakness progressing with age (Table 1) . Patients underwent NCS, EMG, and muscle ultrasound to further characterize the neuromuscular phenotype of the disease. Table 2 summarizes findings of the neurophysiological studies performed in 5 patients. Aside from patient 1 who had absent sural sensory response (likely from a technical reason), but normal median and ulnar sensory responses, all the other 4 patients had preserved sensory responses. The peroneal and tibial compound muscle action potentials (CMAPs) were absent or markedly reduced in 3 patients, with normal distal motor latencies and conduction velocities. Patients 2 and 4 showed normal CMAPs, but patient 2 had intermediate slowing in all motor nerves studied. Needle EMG showed evidence of various severity of chronic partial denervation/reinnervation in all patients and patients 3 and 5 had frequent fasciculation discharges. Thus, their electrophysiological features are most consistent with an anterior horn cell disease or less likely a distal motor neuropathy. Available serial studies in the same patients are also consistent with progressive neuromuscular abnormalities, because electrophysiological studies during infancy were essentially normal, but later in childhood revealed a neurogenic process (patients 1 and 2). Patients 3 and 5 showed mixed small and short and large and long polyphasic motor units with motor unit recruitment more than expected in some muscles giving the minimum contraction of muscles, suggesting possible coexisting myopathic process. Muscle ultrasound revealed severely atrophic and dense muscle with widespread evidence of denervation as evidenced by fasciculating intramuscular movements on real-time ultrasound (see Supplementary Video of muscle ultrasound). Fasciculations were also intermittently noted on exam in tongue and extremities, and were particularly prominent during times of illness. Muscle and nerve biopsies were obtained in infancy (when available) and were overall nondiagnostic.
TBCK p.R126X Is Associated With Epilepsy With Mixed Focal and Generalized Features
All patients developed epilepsy with electroclinical features of focal and generalized seizures, although age of onset and severity of seizures were variable (see Table 1 ). 
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Most children had a history of first seizure in the setting of fever, and then months to years later onset of unprovoked seizures. One patient initially presented at 3 months with infantile spasms and hypsarrhythmia on EEG (electroencephalogram). EEG features include slow and disorganized background early on, with multifocal epileptiform discharges as well as generalized discharges in older patients. Of note, severe adverse reactions leading to prolonged hospitalizations were reported in the 2 patients that were treated with the ketogenic diet, despite normal acylcarnitine profiles.
TBCK p.R126X Mutation Leads to Progressive Leukoencephalopathy and Global Atrophy
Neuroimaging features include progressive volume atrophy, thinning of the corpus callosum, and cerebellar atrophy. Interestingly, some patients who underwent brain MRI in the neonatal period were reported as unremarkable despite profound congenital hypotonia (no images available for review). All patients that underwent MRI after the first year of life had abnormal findings, including scattered abnormal T2 white matter hyperintensities consistent with a leukoencephalopathy. Patient 1 had an episode clinically characterized as a metabolic stroke, in the setting of RSV infection at age 2.5 years, whose MRI findings we previously reported. HYPOTHYROIDISM. Some patients have a history of intermittent hypothermia, with documented temperatures as low as 33 to 34 8C. Hypothermia occurred in the setting of illness, but not consistently; similar temperature fluctuations were also reported when patients were otherwise at baseline. Thyroid studies (thyroid-stimulating hormone; TSH) were available in 7 patients. Three teenage patients were found to have subclinical hypothyroidism, with elevated TSH values ranging from 14.3 to 30.8 (normal, 0.5-3.8uIU/ml).
DYSLIPIDEMIA. We reviewed available lipid panel data given frequently reported history of hypercholesterolemia in our cohort. Table 1 lists a summary of findings, with "dyslipidemia" defined as elevated total cholesterol and/ or triglycerides. Lipid profiles were available in 7 of 8 patients. Total cholesterol was elevated in 5 of 7 patients, with values ranging from 192 to >650 (mean, 371; normal, 107-225mg/dl). Triglycerides were elevated in five of seven available studies, with abnormal values exhibiting a broad range from mild elevations in young age to very significant in teenagers (>1,500mg/dl; normal, 34-165).
OSTEOPOROSIS. Patients reported multiple fractures with minimal trauma, most commonly with femur fractures, but also lumbar spine fractures in 1 patient after a prolonged hospitalization. Further evaluation was consistent with severely decreased bone mineralization. Dualenergy x-ray absorptiometry scans were available in 2 patients. Bone mineral density in nonambulatory children with cerebral palsy have been reported, with mean lumbar Z-score of -1.7.
19 TBCKE patients had remarkably lower scores (although only available in 2 patients), with mean lumbar Z-score of -5.7 (126-2) and Z -5.8 (126-3). Consistent with our observations, a recent report also noted osteoporosis in affected patients with a different mutation in TBCK.
4
GENITOURINARY. Four of the 5 teenage patients have been noted to have urinary retention and renal calculi. Those evaluated by urology were found to have a neurogenic bladder, requiring intermittent catheterization for management. They also experienced frequent recurrent urinary tract infections.
Fibroblasts Homozygous for TBCK p.R126X Have Significant Increase of Autophagosomes
Given that loss of TBCK function has been linked with mTORC1 signaling inhibition, and our previous studies showed that the p.R126X mutation results in premature protein truncation and undetectable levels of TBCK protein, 1 we expected to observe induction of autophagy in patient-derived fibroblasts. LC3 (microtubule-associated protein 1 light chain 3), the mammalian homologue of the autophagy-related Atg8 encoded product in yeast, is a marker for cellular autophagy. Following induction of autophagy, the soluble form LC3b-I (or LC3-I) is modified with a lipophilic moiety to form LC3b-II (or LC3-II). Membrane bound LC3b-II plays a role in forming the phagophore and promoting membrane fusion to form the autophagosome. Immunostaining for LC3b in a punctate pattern is commonly used to detect autophagosomes. Patient-derived fibroblasts under basal culture conditions were probed with LC3b antibodies to detect autophagosomes. A dramatic increase in LC3b- 
LC3b (red) immunostaining of TBCKencephalopathy patients (B) compared to controls (A). Nuclei stained with DAPI (blue)
. Panel (C) shows automated punctae quantification using Zeiss Zen blue software (n 5 51 wild type and n 5 106 TBCK cells from two independent experiments); bars show standard error of the mean, Mann-Whitney U test p value 0.0044. TBCK p.R126X data pooled from three different patient lines (TBCK 126-1, 126-3, and 126-5). LC3 5 microtubule-associated protein 1 light chain 3.
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immunolabled punctae per cell was observed ( Fig. 3 ; wild type mean, 1.4 6 0.54; TBCK mean, 9.4 6 1.7; punctae/cell 6 standard error of the mean), consistent with autophagosomes accumulation in TBCK 2/2 fibroblasts. Given that mTORC1 inhibition is known to increase autophagosome content in cells, this observation FIGURE 4: Western assays from TBCK 2/2 fibroblasts show increased autophagic flux at baseline, but no difference in response to stress or autophagy modulators. Immunoblots for TBCK p.R126X fibroblasts at baseline (complete media) conditions assaying for autophagy markers LC3-I, LC3-II, and p62 (A) were quantified and normalized to GADPH (B). LC3-II/LC3-I ratios are reported as indicative of autophagic flux. Similarly, Beclin-1 levels were assayed (C) and quantified relative to GADPH (D) at baseline conditions. Quantification includes three independent experiments, each including at least two wild type and three TBCK 2/2 lines, each blot was normalized to GADPH, and statistical significance was defined as two-tailed p value of <0.05 using unpaired t test. To determine whether loss-of-function of TBCK affects autophagic response under stress, cells were assayed after 24 hours without serum. Cells were also treated with known autophagy modulators chloroquine (impairs lysosomal function, blocking progression of autophagy) and leucine (enhances mTORC1 signaling). Panel (E) shows results of immunoblots. As seen in panel (F), there is no significant change in the response of controls versus TBCK p.R126X cells under stress or autophagy modulating conditions. GAPDH 5 glyceraldehyde-3-phosphate dehydrogenase; LC3 5 microtubule-associated protein 1 light chain 3; mTORC1 5 mechanistic target of rapamycin complex 1.
is consistent with our previous data suggesting that loss of TBCK results in inhibition of mTORC1 signaling. 2 
TBCK p.R126X Fibroblasts Exhibit Increased Autophagic Flux at Baseline but Not Under Stress
Given the substantial increase in autophagosomes found during routine culture conditions, we assayed fibroblast for LC3-II/LC3-I ratio, which is indicative of autophagic flux. 20 Immunoblots (Fig 4A) showed that TBCKE patient fibroblasts have increased LC3-II/LC3-I ratio at baseline conditions compared to controls (Fig 4B) . Increased autophagic flux is associated with increased p62 levels and TBCKE-fibroblasts showed a trend to increased p62, albeit not statistically significant (Fig 4B) . Under baseline conditions, Beclin-1 levels showed a small, but statistically significant, reduction (Fig 4C,D) in TBCKE-fibroblasts relative to controls. To assess how TBCKE-fibroblasts respond to known stressors and autophagy modulators, we assayed serum-free cells, as well as serum-free cells treated with chloroquine and leucine. Under autophagy induction conditions (serumfree), there was no significant difference in autophagic flux between TBCK and wild-type cells (Fig 4E,F) . Chloroquine is a lysosomal lumen alkalizer, blocking the autophagic progress by impairing lysosomal function, 20 resulting in increased LC3-II/LC3-I ratio. As expected, chloroquine increased autophagic flux, although there was no difference in response between TBCK 2/2 and controls. Because L-leucine stimulates mTORC1 signaling, it is expected to inhibit autophagy under stress conditions. Our previous studies showed rescue of mTORC1 signaling deficits in TBCK-fibroblasts 2 with similar treatment protocol, so we tested whether L-leucine treatment could change autophagic flux. Under serum-free conditions, the 5-hour treatment with 600 lg/ml did not result in significant changes in autophagic flux (Fig 4E) .
TBCK p.R126X Leads to a Deficiency in Oligosaccharide Degradation
Because the autophagic-lysosomal pathway is crucial for the degradation of glycosylated proteins, free sialylated oligosaccharide profiles can provide insight into this cellular process by assaying the by-products of degradation. Previous studies have shown that cells with defects either initiating autophagy or with lysosomal dysfunction accumulate aberrant intracellular free sialylated oligosaccharide species. We therefore tested whether patient-derived fibroblasts with the homozygous TBCK p.R126X mutations exhibit aberrant oligosaccharides profiles. We found that the loss of function of TBCK leads to abnormal accumulation of sialylated oligosaccharide species in patient-derived fibroblasts (Fig 5C) . Treatment of control cells with mTORC1 inhibitor rapamycin also resulted in accumulation of aberrant oligosaccharide species in control fibroblasts in a similar pattern (Fig 5A,B) . Moreover, the aberrant oligosaccharide species in TBCK 2/2 fibroblasts can be partially rescued by treatment with the mTORC1 activator, leucine (Fig 5D) . All the sialylated oligosaccharides diminished after leucine treatment, whereas elevation of GlcNAc1Man2-Man4 persisted. It has been reported before that intracellular sialylated free oligosaccharides are specifically from lysosomal sialic acid transporters whereas GlcNAc1Man2-4 could also come from the endoplasmic reticulum. Given that free oligosaccharides can also be detected in urine, we tested whether the oligosaccharide findings in fibroblasts of patients with p.R126X TBCK mutations were reflected in urine specimens. As shown in Figure 6 , we have found a similar aberrant oligosaccharide pattern in the urine of TBCKE patients. We detected a similar pattern of Although only 1 patient (126-3) had urine glycosaminoglycan (GAG) testing, this was also significantly abnormal for increased total GAG quantity as well as abnormal GAG fractionation pattern, further supporting reduced lysosomal degradation capacity.
Discussion
We describe the distinct neurological phenotype of a subset of patients with homozygous mutations in the TBCK gene that we called TBCK-encephaloneuronopathy. All 8 patients with the Boricua mutation (p.R126X) share a severe phenotype with age-dependent neurodegeneration, including features of motor neuronopathy, which has not been clearly or consistently characterized in previous reports of TBCK associated disease. [1] [2] [3] [4] Common systemic clinical features include hypothyroidism, dyslipidemia, and osteoporosis. We provide evidence that TBCK lossof-function mutations result in inappropriate increase in autophagic flux at baseline conditions, but does not seem to impair autophagic response during stress. Therefore, we provide evidence that autophagic-lysosomal dysfunction may play a role in the pathophysiology of TBCKE. The consistent neuromuscular phenotype observed in patients with the TBCK p.R126X genotype significantly contributes to disease morbidity, given that the progressive neuromuscular weakness results in chronic respiratory insufficiency in all patients by teenage years. All patients who underwent neurophysiological studies (n 5 5) have evidence of motor neuronopathy, although older patients might have additional myopathic features (Table 2) . Interestingly, especially in the setting of acute illness such as respiratory infections, patients exhibit prominent fasciculations, which were visualized in three acutely ill patients using muscle ultrasound (see Supplementary Video). We suspect the neuromuscular involvement in TBCK-associated disease is not exclusive to the Boricua mutation, and likely present in all children with truncating mutations leaving little functional protein activity. In patients who had serial neurophysiological studies, there is evidence that the neuromuscular abnormalities are progressive, consistent with their clinical course. Studies by EMG and muscle ultrasound are most consistent with active denervation as the result of motor neuronopathy. Because we have no muscle biopsies from patients in their teenage years, when myopathic features were observed on EMG, it remains unclear whether myopathic changes are secondary to chronic denervation or the development of an additional myopathy. The latter is conceivable given the multisystemic nature of the disease.
In addition to progressive neuromuscular weakness, our TBCKE cohort clearly exhibits progressive brain degeneration and neurodevelopmental regression. This neurodegenerative aspect of the disease has not been consistently appreciated in previously reported patients with TBCK biallelic mutations. Although all patients reported to date present with hypotonia and delayed milestones, some patients have a milder phenotype, achieving independent ambulation and expressive language without clinical evidence for regression. 2 In contrast, patients in our TBCKE cohort presented with profound hypotonia and global delays in the neonatal period and, subsequently, experienced further developmental regression with loss of skills (such as purposeful reaching or attempting to crawl) later in childhood, typically before 10 years. We submit that cognitive regression is not attributed only to seizures, and more likely attributed to leukoencephalopathy, given that typically at age of regression most children had not yet developed medicationrefractory epilepsy. As shown in Figure 2 , neuroimaging shows progressive global cerebral atrophy and white matter abnormalities. Consistent with an emerging genotype-phenotype correlation for TBCK-encephalopathy, we do have some evidence that patients with TBCK-encephalopathy presenting with a milder and nonprogressive phenotype (siblings previously reported as subjects 4-1 and 4- 2 2 ) have no clinical evidence of neuropathy/neuronopathy and normal EMG/NCS at an age when all Puerto Rican patients have profound weakness and abnormalities in neurophysiological studies.
Compromised autophagic function has emerged as a mechanistic common denominator in many neurodegenerative disorders.
17 mTORC1 inhibitors are well known to induce autophagy, the process by which proteins, lipids, and organelles are trafficked to lysosomes for degradation. 16, 17 Importantly, activation of mTORC1 is also required for autophagy associated lysosome reformation and loss of mTORC1 activation could lead to a reduction in lysosome content. 21 Our studies in TBCKE suggest that chronic mTORC1 inhibition may be detrimental, resulting in inappropriate increase in autophagic flux at baseline conditions. Consistently, we observed a significant increase in accumulation of autophagosomes in TBCK patient-derived fibroblasts (Fig 3) in baseline conditions. Under autophagy-inducing conditions, such as serum deprivation, or in response to autophagy inhibitors such as chloroquine, TBCKE-fibroblasts response did not differ from wild type. Treatment with L-leucine did not significantly alter autophagic flux in serum-free conditions, although it is possible that the short duration of treatment (5 hours) was insufficient to influence autophagic flux. Our past studies with mTORC1 signaling phosphorylation targets showed rescue of phosphorylation deficits at similar dose and exposure time, but under baseline conditions. Further studies should examine whether longer exposure to L-leucine can alter autophagic flux at baseline conditions on TBCKE fibroblasts. However, the increase in autophagosome content does not necessarily imply more efficient degradation. On the contrary, our oligosaccharide profile data suggest that glycosylated proteins are not being properly degraded in TBCK null fibroblasts, implying a possible reduction in lysosome content or lysosomal degradation capacity. Therefore, it is possible that increased autophagosome content and autophagic flux ratios at baseline are indicative of a block in the autophagic-lysosomal cascade, reminiscent of cells treated with chloroquine. This could explain the increased autophagosome content, increased LC3II/LC3I ratios, and impaired degradation of glycosylated proteins at baseline. Further studies should address lysosomal function in TBCKE cells and dissect the steps along the autophagic-lysosomal pathway to better understand the cellular effects of disease causing mutations in TBCK and their role in neurodegeneration. Crucially, future studies need to examine the physiological role of TBCK as it pertains to the regulation of mTORC1 signaling, either by interacting with proteins upstream of the mTORC1 complex or attributed to another yet undetermined mechanism. There are only two reports in the literature regarding TBCK preceding its disease association, and they are conflicting regarding its potential role in regulating cell proliferation. 7, 22 Future animal studies in TBCK knockout mice may be instrumental in determining the physiological role of the TBCK protein and providing further insight into its role in the brain and peripheral nervous system. Aberrant oligosaccharide species can accumulate in cells with defects along the molecular cascade spanning from initiating autophagy to lysosomal degradation. 23 Our free oligosaccharide profile data suggest impaired glycosylated proteins degradation as a consistent finding in patient fibroblasts as well as in urine specimens. Our data are consistent with aberrant autophagic/lysosomal activity resulting from impaired mTORC1 signaling, given that abnormal oligosaccharides can be recapitulated by rapamycin treatment in wild-type cells. Furthermore, the mTORC1 activator, leucine, partially rescues the oligosaccharide profile abnormalities in TBCK 2/2 fibroblasts. Although our data do not show differences in terms of autophagic flux when cells were treated with leucine, the discrepancy could be attributed to different times of treatment (5 hours for flux experiments vs 16 hours for oligosaccharide experiments). Future studies should examine whether long-term treatment with leucine alters autophagic flux, and most importantly to determine therapeutic potential, whether leucine can rescue the phenotype in neuronal models. Further studies will be needed to address whether urine oligosaccharide profile abnormalities are present in all patients with TBCK-associated disease regardless of genotype. Given that patients with the Boricua mutation have a more severe phenotype, it would be interesting to measure profiles in milder phenotype patients to determine whether the severity correlates with the degree of free oligosaccharide excretion. We propose that free oligosaccharide profiles could serve as a biomarker of autophagic-lysosomal dysfunction in this condition.
Our previous studies in TBCK-encephalopathy patient cells also showed that mTORC1 signaling activation with leucine could rescue PS6K phosphorylation deficits. 2 Here, we show partial rescue of aberrant free oligosaccharide accumulation in fibroblasts from TBCKencephalopathy patients treated with leucine, suggesting potential therapeutic relevance of leucine and similar mTORC1 signaling activators. Further studies are needed to determine whether inappropriate autophagy is also present in TBCK-null neurons or glia, and whether leucine can reverse their phenotype. Neuronal and animal models will be of particular relevance given recent reports that autophagy in hippocampal neurons may be independent of mTORC1 signaling. The study of TBCK-associated encephalopathy reveals new insights into the role of overinhibition of mTORC1 signaling in neurodevelopmental disabilities. Specifically, the p.R126X mutation leads to a unique clinical phenotype and may provide additional insight into the link between autophagy and mTORC1 signaling, and links its dysregulation to autophagic-lysosomal pathway dysfunction, and progressive central and peripheral nervous system degeneration.
